In this issue:
Efficacy of glofitamab
High-dose methotrexate for CNS progression
Can microbiome improvements improve clinical outcomes
Comparison of R-CODOX-M/R-IVAC and DA-EPOCH-R
Benefits of GO
Report on post progression OS in novel agent era
Impacts of HSCT in HTLV-1 carriers
Updated article on GLOW study
Long-term follow-up of FCR study
Other malignancies in CLL
Please login below to download this issue (PDF)